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Musculoskeletal (MSK) conditions account for the third 
largest area of NHS program spending (£4.7 billion in 2013-
2014).1,2 Following Lord Carter’s review for the Department 
of Health in 2016,3 there has been an increased focus on 
high-cost procedures and interventions, and on defining, 
mapping, and collecting cost data. This focus includes areas 
such as elective surgical procedures and MSK trauma admis-
sions.3,4 However, there has been significantly less attention 
given to defining costs and collecting widespread compara-
ble MSK cost data in primary and community settings.
Unwarranted variation within the NHS acute sector has 
been estimated at a value of £5bn in terms of an efficiency 
opportunity.3 This was estimated by reviewing all key 
resource areas such as clinical staff, pharmacy and medi-
cines, diagnostics and imaging, procurement, back office 
functions and estates and facilities.3 Identifying variation 
requires the use of these specific metrics as outlined in Lord 
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Abstract
Background: Identifying variation in musculoskeletal service costs requires the use of specific standardized metrics. There 
has been a large focus on costing, efficiency, and standardized metrics within the acute musculoskeletal setting, but far 
less attention in primary care and community settings. Objectives: To (a) assess the quality of costing methods used 
within musculoskeletal economic analyses based primarily in primary and community settings and (b) identify which cost 
variables are the key drivers of musculoskeletal health care costs within these settings. Methods: Medline, AMED, EMBASE, 
CINAHL, HMIC, BNI, and HBE electronic databases were searched for eligible studies. Two reviewers independently 
extracted data and assessed quality of costing methods using an established checklist. Results: Twenty-two studies met the 
review inclusion criteria. The majority of studies demonstrated moderate- to high-quality costing methods. Costing issues 
included studies failing to fully justify the economic perspective, and not distinguishing between short- and long-run costs. 
Highest unit costs were hospital admissions, outpatient visits, and imaging. Highest mean utilization were the following: 
general practitioner (GP) visits, outpatient visits, and physiotherapy visits. Highest mean costs per patient were GP visits, 
outpatient visits, and physiotherapy visits. Conclusion: This review identified a number of key resource use variables that 
are driving musculoskeletal health care costs in the community/primary care setting. High utilization of these resources 
(rather than high unit cost) appears to be the predominant factor increasing mean health care costs. There is, however, need 
for greater detail with capturing these key cost drivers, to further improve the accuracy of costing information.
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Carter’s report and there has been a large focus on costing 
and efficiency in acute care, leading to clear examples of 
unwarranted variation being identified within acute ser-
vices. Hip prostheses, for example, have been shown to 
vary in cost from £788 to £1590 across NHS Trusts, with 
those buying the most not paying the least.3 This work is 
developing within the Model Hospital,4 a digital informa-
tion service set up to support secondary care providers to 
improve productivity and efficiency. The Model Hospital 
demonstrates how appropriately applied metrics can allow 
for a useful comparison of services and their efficiency. 
However, similar economic metrics have not yet been for-
malized or evaluated for MSK primary and community care 
in the United Kingdom.
Economic evaluation is “the comparative analysis of 
alternative courses of action in terms of both their costs 
and consequences.”5 The objectives of health economic 
analyses are to identify, measure, value, and compare 
costs and consequences of alternative treatments/path-
ways of care.5 Economic evaluation techniques therefore 
provide the framework for capturing costs and outcomes/
benefits of different health interventions.6 In this review 
economic costing methodology will be explored, with the 
aim of identifying the most important cost variables for 
making resource use comparisons within primary and 
community MSK settings. The quality of costing methods 
will also be evaluated to determine the strength of these 
findings.
Graves et al7 described 12 criteria for specifically assess-
ing the quality of costing methods of economic analyses. 
These criteria include, for example, stating and justifying 
the perspective, distinguishing between short and long run 
costs, and reporting methods for estimating quantities of 
resources. Graves et al7 reviewed 45 economic analyses 
against the 12 criteria in 2002, and concluded that more 
attention should be given to costing methods to ensure the 
accuracy of costing estimates.
Mogyorosy and Smith8 also reviewed methodological 
issues with costing health care services across Europe in 
2005 and highlighted the usefulness of defining cost driv-
ers. Cost drivers are variables such as medical visits that 
affect costs over a given period of time and can be directly 
linked to changes in costs.9 It is important to identify the 
most relevant cost drivers for a specific setting as these can 
help explain changes or differences in overall costs of care. 
It is also sometimes sufficient and necessary to limit data 
collection (or costing) to the key cost drivers.10 Activity-
based costing looks to improve the accuracy of cost estima-
tion by using multiple cost drivers.8
Costing within economic analyses will differ dependent 
on the perspective, which can include a health perspective 
looking at direct costs to health managers, or a societal per-
spective looking at direct and indirect costs, including pro-
ductivity losses.11 In this review, only direct health care 
costs will be examined in detail as the review looks to iden-
tify key drivers of MSK health care costs only.
This review aims therefore to evaluate the quality of 
costing methods used within MSK economic analyses and 
also to identify the most important cost drivers (provider 
variables) that could be reported by individual primary care 
and community MSK services and used to develop a system 
level methodology to broadly cost and compare these ser-
vices. The perspective will be that of a health service per-
spective looking at costs incurred by MSK patients being 
predominantly treated in community/primary care, as this is 
the area at present where a clear methodology is lacking.
Method
This review followed protocol guidance set out within the 
PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) statement12 (see Supplement 
1 for PRISMA Checklist).
Eligibility Criteria
Inclusion criteria were the following: all types of economic 
analyses, economic analysis needed to be the primary focus 
of the study and clearly stated from the outset, studies pub-
lished within the past 10 years (January 2008 to May 2018) 
in order to ensure applicability of costing approaches, 
English language papers only (due to resource limitations 
of the review), studies primarily set within community or 
primary care health settings to support the focus of the 
paper, patient population to include patients undergoing 
treatment for most prevalent MSK disorders (back, neck, 
shoulder, knee or all MSK conditions,13,14 studies needed to 
report disaggregated health care costs, and papers needed to 
be published in full within a peer-reviewed journal.
Searches
Medline, AMED, EMBASE, CINAHL, HMIC, BNI, and 
HBE electronic databases were searched. Searches were 
limited to papers within the past 10 years only to ensure 
applicability when looking to review costing methods. 
Search terms were grouped into core areas of type of eco-
nomic evaluation such as cost benefit or cost utility,6 study 
type such as analysis or evaluation, and prevalent MSK 
condition such as back, neck, knee, or shoulder.13,14 Searches 
were combined using Boolean logic (AND and OR). 
Additional gray literature was identified using reference 
lists of included articles. Included studies were required to 
have a combination of key search terms (Table 1) within the 
study title, to ensure studies were focused on economic 
evaluation, and not on intervention effectiveness.
The review did not set out to identify every economic 
analysis within the field of MSK, but to systematically 
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identify economic analyses within the field of MSK from 
community/primary care settings that met the inclusion cri-
teria, using a structured, transparent, and reproducible 
search methodology. The full electronic search strategy for 
searching the database Medline can be viewed within 
Supplement 2.
Selection Criteria
One reviewer (RB) reviewed search results and identified 
those based on title and abstract unquestionably excluded 
from the review, and those appropriate for full review. The 
same reviewer (RB) and a second reviewer (JH) then indepen-
dently read full papers for identified studies and determined 
eligibility based on inclusion/exclusion criteria to ensure all 
criteria were met for inclusion into the systematic review.
Data Extraction
Data were extracted using an extraction sheet made up of 
study descriptors such as author, year, title, objectives, set-
ting, population, study size, perspective, outcomes, cost vari-
ables, cost year, costing sources, and analysis type, for 
example, cost-effectiveness analysis (CEA), cost utility anal-
ysis (CUA), cost benefit analysis (CBA), cost consequence 
analysis (CCA). This was followed by the 12 quality criteria 
described by Graves et al.7 Two reviewers independently 
extracted data (RB and JH), one reviewer had a clinical MSK 
background (RB) and one was a health economist (JH). All 
health care costs were extracted and included whether the 
cost was for treatment within primary, community or second-
ary care as although the studies were predominantly set 
within primary care/community clinics, costs were still borne 
by the health care system across all settings (eg, if a patient 
was sent for an investigation or consultant opinion).
The focus of the study was restricted to costs and there-
fore outcomes and specific interventions were not reviewed. 
Detailed costs were reported and analyzed for the usual 
care/control groups only in order to allow for broad com-
parisons of key cost drivers to be made across studies. Due 
to the broad focus of the review (including all common 
MSK conditions) cost drivers were ranked for each study 
rather than being directly compared.
Quality of Costing Methodology
Quality of costing methods within included studies was 
evaluated using 12 criteria described by Graves et al7 and 
following this guidance organized into 4 predefined catego-
ries; general costing issues (criteria 1-4), methods used to 
determine the quantities of resources (criteria 5-7), methods 
used to determine the value of resources consumed (criteria 
8 and 9), and reporting of data (criteria 10-12).7 Quality of 
costing methodology within studies was evaluated indepen-
dently by 2 reviewers (RB and JH) and inputted directly 
into the extraction sheet. A third reviewer was then avail-
able (ML) if agreement could not be reached.
Results
Search Results
A total of 751 records were identified through electronic 
searching of relevant databases. This gave 344 records after 
electronic duplicates were removed (see Figure 1 for detail).
Following initial review of titles and abstracts 276 arti-
cles were excluded for failing to meet the eligibility criteria. 
Following full review of the remaining 68 articles against 
eligibility criteria by the 2 reviewers, 22 studies were suit-
able for inclusion in the review. The main reasons for exclu-
sion were the following: not providing disaggregated costs 
to determine patient-level health care costs, not being under-
taken from the right clinical setting, being a secondary anal-
ysis rather than a preplanned economic analysis, being an 
abstract only, or being a model or review rather than a pri-
mary study.
The majority of studies were economic analyses con-
ducted alongside randomized controlled trials (n = 21) or 
other trial-based analyses (n = 1).15 See Table 2 for charac-
teristics of included studies.
Quality of Costing Methodology in Included 
Studies
The results of quality assessment of costing methodology 
are summarized in Table 3, following criteria set out by 
Graves et al.7
Table 1. Search Terms.
Column 1 (Economic Evaluation 
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Costing Criteria
Category 1: General Costing Issues (Questions 1-4). The 
majority of studies stated the economic perspective (Q1) (21 
out of 22) with a mixture of health care perspective 
(n = 4), societal perspective with disaggregated costs (n = 9), 
both health care and societal perspective stated (n = 8), and 
one with no perspective stated but with disaggregated health 
care costs. The majority of studies did not fully justify their 
perspective (Q2) but simply stated it within their introduc-
tion or methods (7/22 fully justified stated perspective, and 
7/22 partially justified). Studies scored as “partial” for Q2 
did not give an explicit statement but gave some form of 
justification within the introduction/methods for their 
approach such as discussing at length the societal burden of 
the MSK condition then adopting a societal perspective. All 
studies apart from one study16 (and the study without a 
stated perspective17) gave cost data that satisfied the stated 
perspective (Q3).
Category 2: Methods Used to Determine the Quantity of 
Resources Used (Questions 5-7). As within the review by 
Graves et al,7 studies rarely made a distinction between short- 
and long-run costs (Q4) (only 1/22 studies18). Methods for 
quantities of resources used by patients (Q5) were largely 
based on patient self-report cost diaries either collected 
through a questionnaire or through interview that detailed 
resource utilization such as clinical visits to GP (general prac-
titioner), practice nurse, physiotherapist, hospital outpatient 
appointment, day case and other hospital admissions, A&E 
(accidents and emergencies), and prescriptions,19 (21/22 
studies used some form of self-report questionnaire). Other 
methods included using clinician inputted data18 and extract-
ing data from medical databases.16,20 The study by Pinto 
Figure 1. Flowchart of search results.
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et al21 used the Osteoarthritis Cost and Consequences Ques-
tionnaire (OCC-Q) to collect cost data from patients, and 
then cross-checked this information against national GP and 
health information databases. All studies met this criterion.
The majority of studies (20/22) described their methods 
for allocating time for human resources (Q6). Included 
studies mainly used the national average times for each type 
of health care consultation to estimate costs, other studies 
split time for group sessions between participants,22,23 and 
some were unclear.20 Methods for allocating prices between 
patients (Q7) were also often only clear within intervention 
group sessions where the cost was split between patients,23 
or through splitting the cost of intervention training,24 
although some studies detailed splitting the cost for shared 
capital costs such as staff travel and space provided by the 
NHS.22
Category 3: Methods Used to Determine the Value of Resources 
Consumed (Questions 8 and 9). The majority of studies 
(19/22) gave methods for the estimation of prices, unit 
costs, or charges (Q8), with most studies counting all 
resource inputs for each patient such as visits to the GP or 
physiotherapist, and multiplying each by the unit cost to 
provide the direct cost for each group of patients and then 
calculating the mean resource cost per patient. Published 
estimates of unit costs were used by the majority of studies, 
including, for example, UK NHS Reference Costs and Unit 
Costs of Health and Social Care publications by Curtis and 
Burns25 for secondary care and primary care costs respectiv
ely,15,18,19,26-28 the Danish National Health Insurance Service 
Register (primary care), Danish National Patient Register 
(secondary care) and Danish National Prescription Registry 
(medication),16 the Dutch Guidelines or Dutch Central 
Organisation for Healthcare Charges (primary and second-
ary care costs) or the Royal Dutch Society of Pharmacy 
(medication),29,30 or private practice charges.21,31 Lamb 
et al22 stated that intervention costs were estimated using 
in-trial analysis but did not give reference to the full costing 
Table 2. Characteristics of Included Studies.
First Author 
(Reference number) Country/Origin Population RCT Setting
Study Size (No. 
of Patients) Analysis Type
Group Costs 
Reported for in 
Analysis
Barton33 2009 UK OA knee with high 
BMI (>28 kg/m2)
Yes PC 389 CUA Usual care
Bosmans29 2011 Netherlands Subacute neck pain Yes PC and C 146 CUA Usual care
Bultmann20 2009 Denmark MSK disorder Yes C 119 CBA Usual care
Chuang26 2012 UK Chronic LBP Yes PC and C 313 CEA Usual care
Essex19 2017 UK Neck pain Yes PC and C 293 CEA, CUA Usual care
Haines31 2017 Australia Chronic LBP Yes PC and C 112 CEA Usual care
Henchoz32 2010 Switzerland Chronic LBP Yes PC and C 105 CUA Usual care
Hollinghurst27 2008 UK Persistent back pain Yes PC and C 579 CUA Usual care
Hollinghurst18 2013 UK MSK disorder Yes C 2249 CCA and 
CUA
Usual care
Jenson16 2017 Denmark LBP Yes PC 1101 CUA Usual care
Jowett28 2013 UK Shoulder Yes PC and C 232 CUA Usual care
Lamb22 2010 UK Subacute or chronic 
LBP
Yes PC 701 CUA Usual care
Lambeek40 2010 Netherlands Chronic LBP Yes PC and SC 134 CUA Usual care
Marra34 2014 Canada Knee OA Yes PC 139 CUA Usual care
McKenna24 2009 UK Acute shoulder pain Yes PC 200 CEA, CUA Usual care
Pinto21 2013 New Zealand Knee and hip OA Yes PC and C 206 CEA and CUA Usual care
Saha35 2018 Swedan Neck or back pain Yes PC and C 352 CEA, CUA Usual care
Smeets33 2009 Netherlands Chronic LBP Yes C 172 CEA, CUA Combined 
treatment
van de Roer30 2008 Netherlands Chronic LBP Yes C 114 CEA and CUA Usual care
Vermeulen41 2013 Netherlands MSK disorder Yes C 163 CEA Usual care
Werner17 2016 Norway LBP Yes PC 216 CEA Usual care
Whitehurst15 2015 UK LBP No (cohort 
study)
PC 922 CUA Usual care
Abbreviations: C, community; RCT, randomized controlled trial; CEA, cost-effectiveness analysis; CBA, cost benefit analysis; CUA, cost utility 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Burgess et al 7
methods. All studies used more than just hospital charges to 
calculate costs (Q9), including, for example, medication 
costs in addition to hospital charges20,31 or using a variety of 
costing resources.
Category 4: Reporting of Data (Questions 10-12). The major-
ity of studies reported the year cost data were collected 
(Q10), with only 3 studies omitting this level of detail.19,30,32 
The base cost year was also reported for most studies (Q11) 
with this information not present in only 1 study.32 Adjust-
ments for costs made in different time periods (Q12) were 
frequently not necessary due to the majority of studies being 
run over a 12 month period and therefore not needing to 
discount for different time periods, with the exception of 
Barton et al33 who discounted at a rate of 3.5%. The major-
ity of other studies stated adjusting prices for inflation to 
match base cost year.15,16,18,21,22,34
Cost Drivers
Detail of cost drivers extracted across studies included; 
highest resource unit cost, highest resource utilization, and 
highest mean resource cost per patient, where available. 
There was minimal detail however within some studies; for 
example, Barton et al33 had a key cost driver of “visit costs” 
but this was not broken down between different types of 
clinicians. In contrast, detailed visit costs were broken 
down and provided in the study by Hollinghurst et al,18 pro-
viding detail of; hospital care/A&E visit costs, GP home 
visit costs, GP surgery visit costs, GP out-of-hours costs, GP 
telephone consultation costs, district nurse home visit costs, 
practice nurse consultation costs, practice nurse telephone 
consultation costs, and health care assistant/phlebotomist 
costs.
Unit Costs. The highest unit costs were consistently found 
to be outpatient visits/medical specialist visits, hospital 
admissions (day case and hospital stay), and imaging (mag-
netic resonance imaging [MRI], computed tomography 
[CT]). This demonstrates that the secondary care costs 
make up the highest unit costs within MSK health care (see 
Table 4 for further detail and drivers).
Resource Utilization. The highest resource utilization across 
studies was found to be; primary care visits to the GP, out-
patient/medical specialist visits, and physiotherapy visits 
(see Table 5 for further detail and drivers).
Mean Resource Use Cost per Patient. Thirteen studies gave 
data on the mean resource use cost per patient allowing for 
analysis of key drivers of costs within studies. Analysis of 
these studies shows that important drivers of MSK health 
care costs (starting with highest costs) were the following: 
primary care visits to the GP, outpatient/medical specialist 
visits, and physiotherapy visits. This demonstrates that pre-
dominantly high levels of utilization of key resources were 
driving cost, with the top 3 drivers exactly matching those 
for highest utilization (see Table 6a; this table is available 
with costs converted/inflated to GDP 2018 within Supple-
ment 3 as Table 6b). Converted costs, however, need to be 
viewed with caution due to the significant heterogeneity 
between studies including heterogeneity in MSK conditions 
treated, health systems, time horizons, and costing methods. 
Costs therefore cannot be directly compared and have 
instead been ranked within individual studies in order to 
identify the highest cost drivers.
Discussion
This review captured MSK economic analyses across a 
number of varied health systems/nations, including the 
United Kingdom, the Netherlands, Denmark, Norway, 
Switzerland, Sweden, Italy, the United States, Canada, 
Australia, and New Zealand, and focused on trials provid-
ing treatment primarily within primary and community 
health care settings.
Quality of Costing Methods
Only one study18 satisfied all of the costing criteria reported 
by Graves et al.7 The lowest conforming study satisfied 7 of 
the 12 costing criteria (58%),17 which could imply errors in 
costing methods.7 In all, 14/22 (64%) of studies, however, 
satisfied at least 10 or more criteria.
In the review by Graves et al7 in 2002, only 2 out of the 
12 costing quality questions (Q5 and Q8) were satisfied by 
more than 67% of included articles. In this review 10 of the 
12 questions (all except Q2 and Q4) were satisfied by more 
than 77% of included articles.
The quality assessment of costing methods within this 
review demonstrates that more attention still needs to be 
given to the costing methods used to estimate individual 
patient costs with particular attention needed to clarify 
short- and long run-costs and to fully justify the chosen per-
spective. There appears, however, to have been a significant 
improvement with costing within economic analyses when 
these results are compared with the previous similar review 
of 45 economic analyses by Graves et al7 in 2002.
Key Cost Drivers
The highest resource unit costs were secondary care–based 
costs, in contrast to the highest resource utilization, which 
included primary, community, and secondary health care 
drivers, such as GP visits, physiotherapy visits, outpatient/
medical specialist visits, and prescriptions. When these were 
evaluated together to give the mean resource use cost per 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Burgess et al 11
mean resource use costs per patient, showing that the high 
level of utilization rather than the initial unit cost seems to be 
the predominant factor in driving mean costs within MSK 
health care in this setting (see Tables 4-6). These findings 
therefore support a shift in focus for those commissioning 
and evaluating MSK services, from high-cost procedures 
(such as surgical interventions and inpatient stays) within 
MSK health care (largely at a secondary care level) to high 
utilization of key resources such as GP visits and physio-
therapy visits within primary care and community settings, 
with further scrutiny of the cost-effectiveness of the entire 
pathway of MSK health care provision.
We summarized the key drivers of MSK health care 
costs within an international context, and found that the 
highest mean costs across studies (in order) were for: GP 
visits, physiotherapy visits, outpatient medical specialist 
visits, prescription medication, and Hospital Admissions 
(day case and elective stay grouped together). These 5 
drivers captured over 70% of the costs in the majority of 
studies with fully disaggregated costs (7/11 studies). 
Recommendations from the review would be to collect 
detailed costs for the above key drivers particularly with 
regard to GP, physiotherapy, and outpatient visits, which 
formed over 50% of the costs across the majority of stud-
ies (8/11 of those with fully disaggregated costs; these 3 
drivers alone captured over 75% of costs in 2 recent stud-
ies.16,35 This detail might include capturing standard treat-
ment times within clinics (such as 30- or 45-minute 
physiotherapy consultations) and grade of treating clini-
cian (basic grade or advanced level) in order to further 
improve the accuracy of costing for the most important 
cost drivers. Hollingsworth et al18 was the only study to 
detail the treating clinician grade to further improve the 
accuracy of their costing calculation and overall provides a 
useful exemplar of high-quality costing methods within 
community MSK health care. Grieve et al36 supports this 
individualized approach, highlighting that cost-effective-
ness analyses using average unit costs can report inaccu-
rate incremental costs. Clearly, some studies were restricted 
by the research costs and practicalities of collecting this 
level of data, however, capturing this detail would improve 
the accuracy of costing information in this setting as these 
are key cost drivers that are not standardized across MSK 
services, as was too often assumed. This is particularly rel-
evant as significant system changes are made within MSK 
health care such as the introduction of first contact practi-
tioners (FCP) in the United Kingdom, where GPs are being 
replaced in certain areas by advanced MSK physiothera-
pists to assess and manage MSK patients in primary care.37 
Using a standardized mean unit cost for the physiotherapist 
contact in these instances would not take into account the 
seniority of clinicians used or the differing consultation 
times allocated, and could therefore lead to inaccurate 
evaluations of cost.
Additional costs that are useful to collect dependent on 
the perspective of the economic review are; private health 
care professional costs (such as private physiotherapy, acu-
puncture, osteopathy), equipment (including patient aids, 
orthotics, etc) and imaging costs (MRI/X-ray were the most 
important of these).
Limitations of the Review
Limitations of this review were that not all MSK economic 
analyses were included within the review, which means that 
our results cannot be generalized to all MSK economic 
analyses. Non-English studies were also not included due to 
the resource limits of this review. Only direct health care 
costs were reviewed, future studies incorporating additional 
societal costs would be useful to further inform population 
level health systems. This study was a broad review of 
MSK economic analyses and due to this breadth, there was 
a large amount of heterogeneity between studies. This 
means that caution needs to be applied when looking to 
make direct comparisons between studies. Future research 
in this area focusing on one health system or one condition 
would allow for a more detailed and in-depth analysis of 
direct costs. Further review of other sources of activity/
spend data alongside prospective studies evaluating the cost 
drivers identified within this review in primary/community 
MSK services would also be useful to further explore and 
validate findings.
Conclusion
This review provides a detailed overview of the quality of 
costing methods used within MSK economic analyses 
and has identified key drivers of MSK health care costs 
for patients accessing treatment in community and pri-
mary care settings. The quality and accuracy of costing 
data in this setting need more attention around capturing 
the grade of treating clinicians and specific consultation 
length for clinical visits to more accurately determine true 
patient-level costs as these factors were key cost drivers. 
If this information was collected in a standardized, accu-
rate, and consistent manner, it could form a useful part of 
a standardized MSK data set (alongside key metrics mea-
suring treatment outcome/performance) and help develop 
future benchmarking capabilities within these settings 
supporting national data evaluations and informing health 
care policy (such as NHS RightCare in the UK setting).38 
Such an approach would also support a future direction 
toward value-based care (health outcomes achieved per 
monetary unit spent) which looks to achieve good out-
comes in the most efficient way,39 helping form a system 
level framework for restructuring health care delivery for 
the future.
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